EndoChoice Files for $115 Million IPO

ATLANTA, May 6, 2015 /PRNewswire/ -- EndoChoice today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock.  The proposed public offering is expected to consist of common stock offered by EndoChoice.  The number of shares to be sold and the price range for the proposed offering have not yet been determined.  EndoChoice intends to apply to list its common stock on The New York Stock Exchange under the ticker symbol "GI".

J.P. Morgan and BofA Merrill Lynch are acting as joint lead book-running managers for the proposed offering.  William Blair and Stifel are acting as co-managers for the proposed offering.

The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: +1 (866) 803-9204); or BofA Merrill Lynch, Attention: Prospectus Dept., 222 Broadway, New York, NY 10038, or: dg.prospectus_requests@baml.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EndoChoice

Based in the Atlanta GA area, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists screening, diagnosing and treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 25 countries.  The Company was founded in 2008 and has developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy System (Fuse®).

EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.

For more information:

Company Contact
David Gill, Chief Financial Officer
David.Gill@endochoice.com
678-585-1040

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/endochoice-files-registration-statement-for-initial-public-offering-of-common-stock-300078518.html

SOURCE EndoChoice